Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Toronto Dominion Bank

Toronto Dominion Bank boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 27.3% in the third quarter, HoldingsChannel.com reports. The firm owned 15,466 shares of the biopharmaceutical company’s stock after purchasing an additional 3,315 shares during the quarter. Toronto Dominion Bank’s holdings in Alnylam Pharmaceuticals were worth $4,254,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after buying an additional 66,928 shares in the last quarter. TD Asset Management Inc grew its holdings in Alnylam Pharmaceuticals by 6.0% during the second quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock worth $119,055,000 after acquiring an additional 27,592 shares during the period. Charles Schwab Investment Management Inc. raised its position in Alnylam Pharmaceuticals by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after acquiring an additional 16,756 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $97,200,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Alnylam Pharmaceuticals by 0.3% during the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock valued at $103,246,000 after purchasing an additional 1,000 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ALNY. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Piper Sandler reissued an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Chardan Capital reiterated a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Trading Up 0.1 %

Alnylam Pharmaceuticals stock opened at $245.44 on Friday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company’s fifty day simple moving average is $267.01 and its 200-day simple moving average is $248.85. The stock has a market cap of $31.66 billion, a P/E ratio of -93.68 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the prior year, the business earned $1.15 EPS. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% on a year-over-year basis. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CMO Pushkal Garg sold 1,752 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the transaction, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,122 shares of company stock worth $2,540,455. Insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.